Alterations in Stem Cell Populations in IGF-1 Deficient Pediatric Patients Subjected to Mecasermin (Increlex) Treatment

Abstract

Pathway involving insulin-like growth factor 1 (IGF-1) plays significant role in growth and development. Crucial role of IGF-1 was discovered inter alia through studies involving deficient patients with short stature, including Laron syndrome individuals. Noteworthy, despite disturbances in proper growth, elevated values for selected stem cell populations were found in IGF-1 deficient patients. Therefore, here we focused on investigating role of these cells—very small embryonic-like (VSEL) and hematopoietic stem cells (HSC), in the pathology. For the first time we performed long-term observation of these populations in response to rhIGF-1 (mecasermin) therapy. Enrolled pediatric subjects with IGF-1 deficiency syndrome were monitored for 4–5 years of rhIGF-1 treatment. Selected stem cells were analyzed in peripheral blood flow cytometrically, together with chemoattractant SDF-1 using immunoenzymatic method. Patients’ data were collected for correlation of experimental results with clinical outcome. IGF-1 deficient patients were found to demonstrate initially higher levels of VSEL and HSC compared to healthy controls, with their gradual decrease in response to therapy. These changes were significantly associated with SDF-1 plasma levels. Correlations of VSEL and HSC were also reported in reference to growth-related parameters, and IGF-1 and IGFBP3 values. Noteworthy, rhIGF-1 was shown to efficiently induce development of Laron patients achieving at least proper rate of growth (compared to healthy group) in 80% of subjects. In conclusion, here we provided novel insight into stem cells participation in IGF-1 deficiency in patients. Thus, we demonstrated basis for future studies in context of stem cells and IGF-1 role in growth disturbances. Graphical abstract

The role of IGF-1/GH in the aging process and the development of age-related diseases

“…На данный момент терапия СТГ применяется только в педиатрической практике, проводятся клинические исследования по использованию рекомбинантного СТГ для коррекции заболеваний, проявляющихся низкорослостью, но не ассоциированных напрямую с дефицитом СТГ, например при синдроме Тернера, Прадера-Вилли, идиопатической низкорослости [48]. У взрослых и пожилых пациентов не рекомендована заместительная терапия СТГ, что обусловлено высоким риском побочных эффектов -артралгий, миалгий, парестезий и риском возникновения онкологических заболеваний [49]. В РФ не зарегистрированы препараты ИФР-1, в то время как в мировой практике проходят клинические исследования комбинированной терапии СТГ и ИФР-1.…”